Dapagliflozin in the treatment of heart failure with preserved ejection fraction

Česká verzia

Authors: Terézia Švarcová
Authors place of work: Edumed, s. r. o., I. interní kardioangiologická klinika FN Hradec Králové
Published in the journal: Vnitř Lék 2023; 69(4): 261-264
Category: Case reports
doi: https://doi.org/10.36290/vnl.2023.049

Summary

We present obese patient with numerous comorbidities in this case report, who’s treatment of heart failure with preserved ejection fraction (HF PEF) has been managed in our office for several years. The treatment was limited by the patient’s comorbidities (renal failure, obesity, atrial fibrillation, anemia) and by the patient’s preferences. The patient‘s trust and cooperation is essential, as this case report confirms. The patient paid for empagliflozin which he did not tolerate. The patient however was willing to try dapagliflozin at his own expense. Dapaglifllozin was well tolerated by the patient and improved his quality of life significantly. Intolerance of one drug does not necessarily mean intolerance of the whole class. Another member of the same drug class could be beneficial as shown by this case report.

Keywords:

gliflozins – polymorbid patient – heart failure with preserved ejection fraction – patient reimbursement drug

Zdroje

1. Heidenreich P, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022:e263-e421.

2. Borlaug B. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020:559-573.

3. Málek F, Veselý J, Pudil R, et al. Souhrn Doporučených postupů Evropské kardiologické společnosti pro diagnostiku a léčbu srdečního selhání z roku 2021. Cor Vasa 2022;64:121-162.

4. Solomon SD, de Boer RA, DeMets D, et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail. 2021 Jul;23(7):1217-1225.

5. Anker SD, Butler J, Filippatos G, et al. EMPEROR‑Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Oct 14;385(16):1451-1461.